Group 1 - The core point of the news is that Guobang Pharmaceutical (605507) announced a share transfer agreement to introduce a strategic investor, Zhejiang State-owned Capital Operation Company, at a price of 20.66 yuan per share, totaling 791 million yuan [1][2] - After the transfer, the state-owned operation company will hold 6.85% of the shares, becoming a strategic investor without changing the controlling shareholder or actual controller of the company [1] - The transfer is aimed at optimizing the company's equity structure and introducing a strategic investor that recognizes the company's value and future development potential [1][2] Group 2 - The state-owned operation company plans to support the company's comprehensive development in the pharmaceutical field, focusing on industrial chain collaboration, new business incubation, and capital operations [1] - The collaboration will include strengthening personnel exchanges and cooperation in investment project evaluation, new technology validation, scenario applications, and think tank consulting [2] - The introduction of the state-owned operation company as a strategic investor is expected to enhance the company's core competitiveness, resource synergy, and overall operational capability [2]